Related Experiment Video

Updated: Aug 11, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Platelet tests and antiplatelet drugs in coronary artery disease

A C de Boer, P Han, A G Turpie

    Circulation
    |March 1, 1983
    PubMed

    Insights

    Platelet survival time and beta-thromboglobulin (beta TG) levels were not significantly affected by common antiplatelet drugs in patients with coronary artery disease (CAD). This suggests spontaneous variations, not drug effects, influence these cardiovascular markers.

    Area of Science:

    • Cardiovascular Medicine
    • Hematology
    • Pharmacology

    Background:

    • Platelet activation is implicated in coronary artery disease (CAD).
    • Discrepancies exist regarding platelet survival time and beta-thromboglobulin (beta TG) levels in CAD patients.
    • The impact of antiplatelet therapies on these markers requires clarification.

    Purpose of the Study:

    • To investigate platelet survival time and plasma beta TG levels in CAD patients.
    • To evaluate the effect of sulfinpyrazone and aspirin/dipyridamole on these measurements.
    • To resolve literature discrepancies concerning platelet kinetics and drug effects in CAD.

    Main Methods:

    • Determined platelet survival time and plasma beta TG in 48 CAD patients.
    • Conducted a double-blind, crossover trial with placebo, sulfinpyrazone, and aspirin/dipyridamole phases.
    • Compared measurements during different treatment phases and against control values.

    Main Results:

    • CAD patients showed elevated mean plasma beta TG but normal mean platelet survival time.
    • Sulfinpyrazone and aspirin/dipyridamole treatments did not significantly alter platelet survival time or beta TG levels compared to placebo.
    • Observed drug effects were not statistically significant compared to spontaneous variations.

    Conclusions:

    • Platelet survival time and beta TG levels in CAD patients are not significantly influenced by sulfinpyrazone or aspirin/dipyridamole.
    • Spontaneous variations in these markers are more substantial than any measurable drug effect.
    • Current antiplatelet therapies do not appear to alter these specific platelet function tests in CAD.

    More Related Videos

    Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor06:32

    Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

    Published on: May 2, 2025

    Microfluidics in Assessing Platelet Function06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Acute Coronary Syndrome III: Diagnostic Studies01:30

    Acute Coronary Syndrome III: Diagnostic Studies

    Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

    Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

    Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...